At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VERA Vera Therapeutics, Inc.
Closed 11-05 16:00:00 EST
47.70
+2.53
+5.60%
盘后47.70
+0.000.00%
18:58 EST
High48.00Low44.94Vol847.34K
Open45.24D1 Closing45.17Amplitude6.77%
Mkt Cap2.96BTradable Cap2.26BTotal Shares61.97M
T/O39.69MT/O Rate1.79%Tradable Shares47.35M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
BRIEF-Vera Bradley Announces Appointment Of Ian Bickley To The Board Of Directors
Reuters  ·  11-01
BRIEF-Vera Bradley Announces Appointment Of Ian Bickley To The Board Of Directors
Vera Therapeutics 7.14M share Secondary priced at $42.00
TIPRANKS  ·  10-30
Vera Therapeutics 7.14M share Secondary priced at $42.00
Stock Track | Vera Therapeutics Plunges 9% After Pricing $300 Million Stock Offering
Stock Track  ·  10-30
Stock Track | Vera Therapeutics Plunges 9% After Pricing $300 Million Stock Offering
BRIEF-Vera Therapeutics Prices Public Offering Of 7.1 Mln Shares At $42.00 Per Share
Reuters  ·  10-30
BRIEF-Vera Therapeutics Prices Public Offering Of 7.1 Mln Shares At $42.00 Per Share
Vera Therapeutics Inc - Prices Public Offering of 7.1 Mln Shares at $42.00 per Share
THOMSON REUTERS  ·  10-30
Vera Therapeutics Inc - Prices Public Offering of 7.1 Mln Shares at $42.00 per Share
Vera Therapeutics Announces Pricing of Public Offering of Class a Common Stock
THOMSON REUTERS  ·  10-30
Vera Therapeutics Announces Pricing of Public Offering of Class a Common Stock
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
GlobeNewswire  ·  10-30
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
BUZZ-Vera Therapeutics slips after unveiling $300 mln stock offering
Reuters  ·  10-29
BUZZ-Vera Therapeutics slips after unveiling $300 mln stock offering
Vera Therapeutics Advances Atacicept with Promising Trial Results
TIPRANKS  ·  10-29
Vera Therapeutics Advances Atacicept with Promising Trial Results
BRIEF-Vera Therapeutics Files For Mixed Shelf Offering
Reuters  ·  10-29
BRIEF-Vera Therapeutics Files For Mixed Shelf Offering
BRIEF-Vera Therapeutics Announces Proposed Public Offering Of Class A Common Stock
Reuters  ·  10-29
BRIEF-Vera Therapeutics Announces Proposed Public Offering Of Class A Common Stock
Vera Therapeutics announces $300M offering of Class A common stock
TIPRANKS  ·  10-29
Vera Therapeutics announces $300M offering of Class A common stock
Vera Therapeutics Inc - to Commence $300 Million Public Offering
THOMSON REUTERS  ·  10-29
Vera Therapeutics Inc - to Commence $300 Million Public Offering
Vera Therapeutics Announces Proposed Public Offering of Class a Common Stock
THOMSON REUTERS  ·  10-29
Vera Therapeutics Announces Proposed Public Offering of Class a Common Stock
Press Release: Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
Dow Jones  ·  10-29
Press Release: Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
Vera Therapeutics files automatic mixed securities shelf
TIPRANKS  ·  10-29
Vera Therapeutics files automatic mixed securities shelf
Vera Therapeutics Inc Files for Mixed Shelf Offering; Size Not Disclosed- SEC Filing
THOMSON REUTERS  ·  10-29
Vera Therapeutics Inc Files for Mixed Shelf Offering; Size Not Disclosed- SEC Filing
Sector Update: Health Care Stocks Rise Late Afternoon
MT Newswires Live  ·  10-29
Sector Update: Health Care Stocks Rise Late Afternoon
BUZZ-Vera jumps on additional mid-stage study data for kidney disease drug
Reuters  ·  10-28
BUZZ-Vera jumps on additional mid-stage study data for kidney disease drug
Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years
Benzinga  ·  10-28
Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years

Introduction

Company Name.
Vera Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Issue price:
--